Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Osiris Therapeutics Inc (NASDAQ:OSIR)

Delayed Data
As of Feb 11
 +0.14 / +2.14%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. The segment, using mesenchymal stem cell technology offers two biologic drug candidates, Prochymal and Chondrogen which has anti-inflammatory properties. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. The segment manufactures markets and distributes Grafix and Ovation for tissue repair. Osiris Therapeutics was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

Contact Information

Osiris Therapeutics, Inc.
7015 Albert Einstein Drive
Columbia Maryland 21046-1707
P:(443) 545-1800
Investor Relations:
(443) 545-1834



Individual stakeholders44.79%
Mutual fund holders14.39%
Other institutional13.72%

Top Executives

Bobby Dwayne MontgomeryChief Executive Officer
Frank D. CzworkaChief Operating Officer
Gregory LawChief Financial Officer, Secretary & Treasurer
Alla DanilkovitchChief Scientific Officer
Jonathan Mark HopperChief Medical Officer